Latest Headlines

  1. UCLA Receives $13M Contract To Expand COVID-19 Testing 9/20/2021

    A new $13.3M contract from the National Institutes of Health’s Rapid Acceleration of Diagnostics initiative, or RADx, will enable the David Geffen School of Medicine at UCLA to expand its capacity to process COVID-19 tests.

  2. LabVantage Solutions Introduces LabVantage Enterprise SaaS 9/15/2021

    LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the introduction of LabVantage Enterprise SaaS.

  3. InBios Receives FDA EUA For COVID-19 IgG Antibody Rapid Test 9/15/2021

    InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SCoV-2 Detect IgG Rapid Test, a qualitative immunoassay for the detection of IgG antibodies to SARS-CoV-2.

  4. Predictive Health Diagnostics Company Announces Rollout Of Proprietary LIS Cloud-Based Laboratory Information System Software 9/15/2021

    Predictive Health Diagnostics Company, Inc. ("PHDC" or "the Company"), a diagnostics platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics that detect diseases with significant unmet medical needs and support better therapeutic outcomes, today announced the rollout of their internally developed proprietary Laboratory Information System (LIS).

  5. CS Analytical Laboratory Expands Laboratory Service Offering With Addition Of ASTM 4169 Package Distribution Testing 9/15/2021

    CS Analytical Laboratory, the world’s only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has expanded its service offering to include ASTM 4169 “Standard Practice For Performance Testing Of Shipping Containers And Systems” and other relevant ISTA (International Safe Transit Association) test procedures.

  6. Tesis Labs To Provide Genetic Testing Services For Premier Health ACO With Operations Throughout Georgia 9/15/2021

    Tesis Labs, the leader in targeted genetic sequencing, announced it has been selected by Premier Health, an accountable care organization (ACO) serving communities in Georgia to provide clinicians and practices in the ACO with high-complexity molecular and next-generation sequencing (NGS) testing services for detecting chronic and hereditary conditions in patients.

  7. bioAffinity Technologies Announces Precision Pathology Services’ Validation Of Novel Non-Invasive Early Lung Cancer Test 9/14/2021

    bioAffinity Technologies, a privately held biotech company advancing innovative cancer diagnostics, announced that Precision Pathology Services, a CAP/CLIA-certified anatomic and clinical pathology laboratory, has fully validated the clinical performance of CyPath Lung, a non-invasive flow cytometric test for early-stage lung cancer.

  8. Seneca Therapeutics, Inc. Announces Novel SVV-001 Patient Screening Test For Patient Selection With SVV-001 Therapy 9/14/2021

    Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics for cancer based on Seneca Valley Virus (SVV-001), announced today the successful development of a novel SVV-001 Patient Screening Test.

  9. Successful Alpha Testing Of Biofidelity's ASPYRE-Lung Reagents Demonstrates Breakthrough Capabilities And Ease Of Use 9/14/2021

    Biofidelity Ltd, the cancer diagnostics company, today announced the successful completion of alpha testing of its new ASPYRE-Lung reagents at multiple laboratory locations in the US and UK.

  10. Quanterix Receives Label Expansion On Emergency Use Authorization For COVID Antigen Test 9/13/2021

    Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that the Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) label for its Simoa SARS-CoV-2 N Protein Antigen Test to include testing with nasal swab and saliva samples, and for asymptomatic serial testing with nasal swab samples.